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Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new coronavirus, was diagnosed in China in 
December 2019. Around the globe, a total of 71 429 were infected up to February 17, 2020, with 98.9% of cases in China. On 
March 11, 2020, the World Health Organization (WHO) characterized the COVID-19 as ‘pandemic’. Rapid positive worldwide 
incidence was the motivation behind this study to investigate the incidence and mortality globally.
Methods: We used the data published by the WHO until March 9, 2020. Non-parametric tests and change point analysis were 
used for inferences. 
Results: Change point analysis for Iran and China and the world excluding China for the first 20 days revealed around 78, 195 
and 2 further new cases per day, respectively. Italy had a big jump in incidence on the 36th day. Similarly, a sharp rise of positive 
cases was reported for the world on the 35th day. China successfully controlled the ascending reports of incidence on the 23rd 
day. Mortality in China and the world were almost similar for the first 20 days. There was an ascending incidence trend with two 
change points in Italy (30th and 36th days) and one change point in Iran on the 17th day. Mortality in the world jumped remarkably 
after day 42 with an estimation of almost more than 25 deaths per day. 
Conclusion: The incidence of COVID-19 varied by regions; however, after March 11, it became ‘pandemic’. It was observed that 
after about 6 days with an emergence of sharp increase in incidences, there would be a mutation in mortality rate. On the other 
hand, the importance of ‘on-time’ quarantine programs in controlling this virus was confirmed.
Keywords: COVID-19, Incidence, Mortality
Cite this article as: Chaibakhsh S, Pourhoseingholi A, Vahedi M. Global incidence and mortality rate of COVID-19; special focus 
on Iran, Italy and China. Arch Iran Med. 2020;23(7):455–461. doi: 10.34172/aim.2020.42.
*Corresponding Author: Asma Pourhoseingholi, PhD; Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical 






Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), a new coronavirus, was diagnosed in Wuhan, 
Hubei province, China, in December 2019.1 This novel 
virus rapidly spread to all provinces of China and 25 
countries in the Asia-Pacific Region, North America, 
Europe, and South America within 1 month of its 
discovery.2
The origin of SARS-CoV-2 is assumed to be from 
bats; it moved to intermediate hosts before transmitting 
to humans, resulting in a pneumonia which is similar to 
the other coronaviruses such as the SARS-CoV and the 
Middle East Respiratory Syndrome-associated coronavirus 
(MERS-CoV).3-5
Although the International Committee on Taxonomy of 
Viruses (ICTV) classified this novel virus as SARS-CoV-2, 
on February 11, 2020, this novel virus was renamed as 
the ‘coronavirus disease 2019’ (COVID-19) by the World 
Health Organization (WHO). Worldwide, a total of 71 
429 were infected as of February 17, 2020 with 70 635 
(98.9%) cases occurring in China. Also, 1772 deaths 
were reported in China with a crude mortality of 2.5%.6 
Finally, on March 11, 2020, the WHO characterized the 
COVID-19 as pandemic.7
The first report of outbreak in Iran was on February 20.8 
Qom, a city in central Iran near the capital Tehran (the 
distance between Qom and Tehran is 148 km and about 
92 miles), was considered as the first place for the outbreak 
of COVID-19 in Iran. The infection rapidly disseminated 
to all provinces of Iran within 15 days. 
A similar situation as Iran occurred in Italy, which is 
in Europe. The first case of COVID-19 was reported on 
January 13,9 and the rapid spread of contagion in Italy after 
February 21 was considerable. Iran and Italy faced with an 
unexpected situation with rapid spread of contagion. 
In this study, we aimed to conduct a global comparison 
according to incidence and mortality rates and identifying 
the dates with considerable mutation in the trend of 
incidence and mortality rates. Similarly, due to the large 




 Arch Iran Med, Volume 23, Issue 7, July 2020                                                        456
Chaibakhsh  et al 
between China, Iran and Italy and the world according to 
incidence rate and mortality rates until March 9, 2020. 
Material and Methods
Data Source
We used the data that was collected and disseminated by 
the WHO about the coronavirus regarding confirmed, 
recovered, and death cases. The data reported from 
January 22, 2020 is updated daily and available on the 
RamiKrispin dataset.10
Cumulative Incidence and Mortality Rate until March 9, 
2020
For the global comparison of incidence rate and mortality 
rate, we divided the world into five regions according to 
the WHO.2 We excluded China as it was the origin of the 
virus and an outlier.
Incidence and mortality rate of the five regions were 
compared. Also, the relationship between Human 
Development Index (HDI) and incidence and mortality 
rate were measured. HDI is a statistic composite index 
of life expectancy, education, and per capita income 
indicators, which are used to rank countries based on 
human development. A country scores a higher HDI when 
the lifespan, education level and gross national income per 
capita are higher.11 
Trend Analysis
The global trend of incidence, mortality rate and the 
critical days with an increase or decrease in trend were 
identified. The same process was performed to assess the 
trend of incidence and mortality rate in Italy and China. 
In order to obtain further information, the data pertaining 
to China was omitted from the global data and the analysis 
was repeated.
Another comparison was made using the data of the first 
20 days from global reports, China and Iran. Truncating 
the other information made it possible to compare the 
trend between Iran and China and the world – the 20 days 
for Iran were reported until March 9. 
Statistical Analysis
The relationship between continuous data was assessed 
using Spearman correlation. To compare the incidence and 
mortality rates, the Kruskal-Wallis test was used. Trends 
analysis were performed using change point analysis. 
‘Change-point analysis’ is a technique to assess the critical 
and multiple change-points over the long-term population 
and health trends. The term ‘change-point’ describes the 
time at which a change began to occur. However, in long 
period data, we can have more clear pattern and time 
shifts.12 All analyses were performed using the SPSS 22 
and Joinpoint software. P values <0.05 were considered 
significant.
Results
A total of 63 countries were included in the study. Countries 
with fewer than two reported cases and incomplete death 
information were omitted. The highest incidence and 
mortality rates after China pertained to San Marino and 
the Philippines, respectively, and the lowest ranks belonged 
to Indonesia and the Netherlands, respectively. 
Global Overview of COVID-19 Incidence and Mortality 
Rates
As mentioned before, the whole world was divided into 
five regions. Then, the incidence and mortality rates were 
compared according to these five regions. The lowest and 
highest mortality rates were observed in the European 
region and the Western Pacific Region, respectively. 
Likewise, the lowest and highest incidence rates were 
reported from the European region and Africa, respectively. 
Comparison according to incidence showed a significant 
statistical difference (P value = 0.015). Accordingly, on ‘two 
by two’ comparison, the incidence in the European region 
vs. the African region (44.17 per 1 000 000 vs. 0.25 per 
1 000 000, P value = 0.025), the European region vs. the 
Americas (44.17 per 1 000 000 vs. 0.67 per 1,000,000, P 
value = 0.008) and the European region vs. the South-East 
Asian region (44.17 per 1 000 000 vs. 1.36 per 1 000 000, 
P value = 0.035) were statistically different (Table 1). 
The HDI of each country was used according to the 
WHO reports. Incidence differed significantly between 
countries with different HDI (r = 0.70, P value ≤0.001); 
with increasing HDI, incidence was raised. However, we 
did not find any significant correlation between this index 
Table 1. Global Overview of Incidence and Mortality Rate
Region
Incidence Per 1 000 000
 P Value
Mortality Rate Per 1 000 000
P Value
n Mean CI SD Mean CI SD




Eastern Mediterranean 13 11.06 (0–40.76) 21.43 1.24 (0–2.68) 2.64
European 28 44.17 (0–101.46) 154.68 0.45 (0.06–0.84) 1.04
Region of the Americas 5 0.67 (0–1.19) 0.59 1.03 (0–3.05) 2.31
South-East Asia 4 1.36 (0–3.55) 2.23 0.50 (0–1.48) 1.00
Western Pacific 9 35.21 (0–95.69) 92.57 2.53 (0–6.1) 5.47
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and mortality rate (r = 0.11, P value = 0.403). 
Trend of Incidence and Change Points over Time
Trend of Incidence in China, Italy and Globally
The first COVID-19 case was reported in China on 
January 22, 2020. The first reports from Italy and Iran 
came on January 31, and February 20, respectively. 
However, the information of only two days was reported 
from Italy during the first 20 days. 
First, based on the global analysis, there was a significant 
global trend (P value <0.001) during the first 14 days, 
estimating 315 further new cases every. From the 15th to 
35th day, the number of new cases per day was significantly 
lower compared with the previous day (P value <0.001). 
New cases per each day decreased by about 148 compared 
to the previous day. Then on the 36th day, a significant 
increase occurred again (P value <0.001) although the new 
cases in each day were lower compared to the first 20 days 
(about 227 further new cases each day) (Figure 1A). 
The trend of incidence in China, like the rest of the 
globe, increased significantly (P value <0.001). However 
new cases added were lower compared to the previous day 
(about 150 cases). Then, for the rest of the days, there was 
a significant descending slope (P value <0.001) with an 
estimation of -207 (Figure 1B). In other words, on average, 
the new cases would diminish by 207 compared to new 
cases of every previous day. In the next step of our analysis, 
China, as an outlier, was omitted from the global analysis 
and the results showed only one change point. Although 
a significant increasing trend was detected, the number of 
further new cases reported every day was about 8 during 
the first 35 days which then increased to about 303 (both 
P value < 0.001). As for Italy, we analyzed from the first 
day of the outbreak until April 9 due to lack of data for 
the first 20 days in Italy. Italy had a statistically significant 
ascending slope but with two change points. During the 
first 27 days, no significant trend was detected, but on 
the 28th day, there was a change point which showed a 
significant positive trend. The results showed that each 
day, about 63 new cases would be added (P value < 0001). 
A remarkable change occurred on the 36th day which 
showed a large outbreak. An ascending trend ensued with 
a steeper slope (P value < 0.001) compared to the previous 
days. The estimation showed that on average, 286 new 
cases would be added every day to the previous new cases 
(Figure 1C).
Comparing Incidence Trend in the First 20 Days in China, 
Iran and Globally
In the first 7 days of the outbreak in Iran, there was 
no significant trend but from the 8th day, a significant 
ascending trend occurred (P value < 0.001). The estimated 
slope showed that about 78 new cases would be added 
per day (Figure 1D). The change point analysis showed a 
positive significant trend with a no change point in China 
(195 further cases per day, P value < 0.001) and the world 
Figure 1. (A) Global, (B) Chinese, (C) Italian and (D) Iranian incidence trend until March 9. 
(A) (B)
(C) (D)
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(197 further cases per day, P value < 0.001) (Figure 2A 
and 2B). 
Trend of Mortality in China, Italy and the Globe
The change point analysis of mortality was the next step 
of analysis. The information of mortality in the world 
estimated the addition of approximately six new deaths 
per day until day 24 (P value < 0.001). After that, the slope 
showed a significant descending trend with the estimation 
of approximately 5 (P value = 0.002) until the 42nd day of 
the outbreak. From the 43rd day (the next change point), 
suddenly a positive significant trend occurred (almost 
25 new deaths were added per day P value < 0.001). 
Estimations demonstrated further mortality compared to 
the first ascending interval (25 added new deaths per day) 
(Figure 3A). Similar to the global mortality, China had an 
ascending trend until the 24th day (6 new deaths per day, 
P value < 0.001) and following the trend, suddenly there 
was a significant decline in trend (5 fewer new deaths 
per day, P value < 0.001) emerged and continued until 
the last day (Figure 3B). Although there were two trend 
change points in Italy (Figure 3C), there was an ascending 
trend from the beginning of the outbreak to the last day. 
In the first 30 days, it was estimated that each day about 
1 death occurred more than the previous day (P value = 
0.001). After that period, from the 31st to the 36th day, the 
estimation increased to almost 8 cases (P value < 0.001). 
(A)
(B)
Figure 2. (A) Global and (B) Chinese Incidence Trend in the First 20 Days 




The results showed a sharp increase in mortality after day 
36. We estimated about 40 more new deaths until the last 
day (P value < 0.001). 
Comparing Mortality Trend in the First 20 Days in Iran 
and the Globe 
There was a significant increasing trend in the globe (P 
value < 0.001) (Figure 4). Five new cases per day were 
expected in Iran similar to the global estimate. There was 
an ascending significant trend, but on the 17th day, there 
was a change point which showed that the expected further 
new cases were increased. The results illustrated that until 
the 17th day, approximately 1 new more death would occur 
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in the next day, while the estimation for the time after the 
17th day was about 12 further new deaths (Figure 5).
The global mortality during the first 20 outbreak days 
was almost similar to China. Thus, the results of China 
were not reported.
Discussion
This study provides an overview of incidence and mortality 
rate patterns on the global level with special attention to 
Iran, Italy and China as the countries most involved with 
COVID-19. 
The WHO has published the data since January 22, 
2020 and it is updated on a daily basis. We used this data 
until March 9, almost three months after the first report 
of the outbreak in China. Finally, on March 11, the 
WHO announced that COVID-19 can be characterized 
as ‘pandemic’. This announcement shows the importance 
of the global investigation of incidence and mortality. 
Nevertheless, we did not find any statistical difference in 
mortality rates by regions while a significant variety of 
incidence was found in different regions. These results 
show that although some risk factors such as regional 
characteristics could affect incidence, the risk factors 
associated with mortality are not related to the region, and 
genetic parameters might have affected mortality. 
On the other hand, analyzing the correlation between 
HDI index and incidence confirms that countries with 
high development scores would experience a high incidence 
rate of COVID-19. This finding might be explained by 
the fact that developed countries have better access to 
diagnostic methods for rapid diagnosis, registration and 
reports. For example, as of March 9, there has been no 
report from countries such as Syria or some poor African 
countries like Somalia. It confirms that these countries do 
not have the facilities or even a stable government to check 
and test patients and report to the WHO. In addition, one 
cannot overlook the fact that developed countries are more 
connected to other countries due to greater trade, tourism, 
etc. These communications may result in easier and faster 
spread of the virus in these countries, as the virus spread 
rapidly across China during the first days of outbreak, even 
with quarantine in effect. There was not any significant 
correlation between HDI and mortality rate, suggesting 
that developed countries were not safe from mortality and 
advanced treatments were not effective. 
Two other previous versions of the coronavirus that 
affected the world were the SARS-CoV and the MERS-
CoV. SARS-CoV was identified in 2003 and first infected 
humans in the Guangdong province of southern China 
in 2002.13 The MERS-CoV infection was first reported 
in September 2012 in Saudi Arabia, but an outbreak in 
Jordan in April 2012 was confirmed retrospectively.14 
There is a paucity of data on the incidence of SARS and 
MERS in the literature. It seems that the incidence of 
these two coronaviruses was not as important as that of 
COVID-19 because neither of them became pandemic 
as COVID-19 did. 
Following southern China, SARS occurred in Toronto 
in Canada, the Hong Kong Special Administrative 
Region of China, Chinese Taipei, Singapore, and Hanoi 
in Vietnam. The most reported cases of MERS after 
the Arabian Peninsula were in the Republic of Korea in 
2015. Cases were also confirmed in countries throughout 
Europe, Asia, North Africa, the Middle East, and the 
United States.6
While the incidence of SARS and MERS were lower 
than COVID-19, the mortality rate of COVID-19 has 
been considerably lower than them. According to the 
WHO reports, the mortality rates of SARS-CoV and 
MERS-CoV were about 9.6% and 36%, respectively15,16 
while it is about 3% For COVID-19. 
COVID-19 is pandemic and it seems that the rapid 
contagious spread of this virus makes it an emergency to 
study the incidence rates and make comparisons between 
different regions of the world. Although COVID-19 is 
more widespread and needs more attention in different 
regions, there are some studies that have investigated 
mortality and some risk factors associated with mortality 
in SARS and MERS in specific countries.14 For example, 
one study investigated if the infection control measures 
Figure 4. Global Mortality Trend in the First 20 Days of Outbreak. Figure 5. Iranian Mortality Trend until March 9. 
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during the 2003 SARS outbreak in Toronto were 
associated with a change in overall population mortality.17 
In another study from Saudi Arabia, the authors 
reported the 3- and 30-day survival rates and their risk 
factors in a large MERS-CoV population.18 Some other 
epidemiological studies have investigated the clinical 
predictors or risk factors associated with mortality.19,20
Due to the rapidly increasing incidence trend of 
COVID-19, studies are still mostly focused on controlling 
and prevention issues or virology studies.21-24 However, 
in the current study, using a special statistical method, 
we focused on incidence and mortality rate trend in the 
world. Until March 9, Iran and Italy made a dramatically 
change in the worldwide incidence. We addressed these 
two countries separately in this research. Also, China, as 
the origin of COVID-19, was considered separately.
Change point analysis showed an ascending trend in the 
world and all the mentioned regions except China, which, 
unlike other regions, has shown success in controlling 
COVID-19 from day 23. It seems that the regular, timely 
quarantine program was the key point of this success. After 
day 23, according to the results of change point analysis, 
the daily incidence decreased by 207 cases on average. 
Italy had the most rapid increase in our comparisons. The 
entire northern Italy was first placed under quarantine, 
but this move did not succeed in controlling the spread of 
the virus, necessitating quarantine in the entire country. 
Following these measures, the slope of incidence was still 
ascending. Therefore, the appropriate time for starting 
quarantine is important for controlling the spread of the 
virus. 
In this regard, Iran did not establish any quarantine. 
Comparing the first 20 days of outbreak between China, 
Iran and the world shows that although China could 
control the infection on the 23rd day (may be due to 
establishing quarantine), the speed of transfer of the virus 
was greater in China compared to Iran. This result shows 
that being aware of the new infection with COVID-19 
could facilitate controlling the incidence sooner.
Another interesting finding in our results was the time 
gap between the jumping point in mortality and incidence 
rate of the world, which was almost six days. In other 
words, six days after a rapid rise in the global incidence 
rate (day 36), we observed a rapid rise in mortality rate 
(day 42). This may be helpful in knowing the interval 
from diagnosis to death. 
In conclusion, the following points may be important 
findings of our study. First, the incidence of COVID-19 
was different in various regions; however, after March 
11, it turned into a pandemic. The time gap between 
jumping point in global mortality and incidence rates was 
almost six days. It means that on average, death occurred 
six days after the outbreak. This might be helpful in 
medical emergencies for saving patients and predicting 
mortality rate on a specific day. On the other hand, China 
managed to control the increasing outbreak on day 23. 
This highlights the importance of quarantine plans in 
controlling this virus at the right time.
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